Plain-English translation of NCT07452601 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy drug called adebrelimab combined with chemotherapy to treat advanced esophageal squamous cell carcinoma (a specific type of esophageal cancer) before surgery. The unique focus of this study is exploring whether the time of day you receive the medication affects how well it works and how your body tolerates it.
Recent research suggests that the timing of immunotherapy may influence how effectively it works, since the immune system naturally varies throughout the day. This study aims to determine whether giving this medication at specific times—morning, afternoon, or a combination—improves treatment outcomes for patients with advanced esophageal cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three groups that differ only in the time of day you receive your treatment infusions. All participants receive three cycles of the medication combined with chemotherapy over several weeks, followed by surgery 4 to 6 weeks after your final treatment. You'll have regular visits for blood tests, scans to monitor your cancer, and checkups, with ongoing follow-up appointments after surgery to monitor for recurrence and assess your recovery.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China